TR200003844T2 - Epotilon türevleri, sentezleri ve kullanımları - Google Patents

Epotilon türevleri, sentezleri ve kullanımları

Info

Publication number
TR200003844T2
TR200003844T2 TR2000/03844T TR200003844T TR200003844T2 TR 200003844 T2 TR200003844 T2 TR 200003844T2 TR 2000/03844 T TR2000/03844 T TR 2000/03844T TR 200003844 T TR200003844 T TR 200003844T TR 200003844 T2 TR200003844 T2 TR 200003844T2
Authority
TR
Turkey
Prior art keywords
unit
units
group
single bond
present
Prior art date
Application number
TR2000/03844T
Other languages
English (en)
Inventor
Costa Nicolaou Kyriacos
Paul King Nigel
Raymond Verschoyle Finlay Maurice
He Yun
Roschangar Frank
Vourloumis Dionisios
Vallberg Hans
Bigot Antony
Original Assignee
Novartis Ag
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, The Scripps Research Institute filed Critical Novartis Ag
Publication of TR200003844T2 publication Critical patent/TR200003844T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Silicon Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut bulus, asagidaki formülle gösterilen bir epotilon analogu ile ilgili olup, R2 birimi bulunmayan ya da oksijen olan; ''a'' tek ya da çift bag olabilen; ''b'' birimi bulunmayan ya da bir tek bag olan; ve R2 grubunun oksijen olmasi halinde ''b'' ve ''c'' birimlerinin her ikisi bir tek bag ve ''a'' biriminin de bir tek bag olmasi; R2 grubunun mevcut olmamasi halinde ''b'' ve ''c'' birimleri de mevcut olmayan ve ''a'' biriminin bir çift bag olmasi; ve ''a'' biriminin bir çift bag olmasi halinde R2, ''b'' ve ''c'' birimlerinin mevcut olmamasi sartlari ile ''c'' birimi ya mevcut olmayan ya da bir tek bag; R3 birimi, hidrojen; düsük alkil; -CH=CH2; -C=CH; -CH2F; -CH2Cl; -CH2-OH; -CH2-O-(C1-C6-alkil); -CH2-S-(C1-C6-alkil); olusan gruptan seçilen bir radikal; R4 ve R5 birimleri birbirinden bagimsiz olarak hidrojen, metil ya da koruyucu; ve R1, sartnamede tarif edildigi gibidir veya bir tuz olusturucu grubun mevcut olmasi durumunda I formülü bilesiginin bir tuzudur (DEVAMI VAR).
TR2000/03844T 1998-06-22 1999-06-21 Epotilon türevleri, sentezleri ve kullanımları TR200003844T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/102,602 US6380394B1 (en) 1996-12-13 1998-06-22 Epothilone analogs

Publications (1)

Publication Number Publication Date
TR200003844T2 true TR200003844T2 (tr) 2001-04-20

Family

ID=22290705

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03844T TR200003844T2 (tr) 1998-06-22 1999-06-21 Epotilon türevleri, sentezleri ve kullanımları

Country Status (28)

Country Link
US (3) US6380394B1 (tr)
EP (2) EP1089998B1 (tr)
JP (1) JP4681732B2 (tr)
KR (3) KR20090066332A (tr)
CN (1) CN1192031C (tr)
AT (1) ATE343573T1 (tr)
AU (1) AU757854B2 (tr)
BR (1) BR9911420A (tr)
CA (1) CA2334342C (tr)
CY (1) CY1105863T1 (tr)
CZ (1) CZ301783B6 (tr)
DE (1) DE69933767T2 (tr)
DK (1) DK1089998T3 (tr)
ES (1) ES2273502T3 (tr)
HK (1) HK1038358A1 (tr)
HU (1) HUP0102711A3 (tr)
ID (1) ID28210A (tr)
IL (3) IL139784A0 (tr)
MX (1) MXPA00012443A (tr)
NO (1) NO328417B1 (tr)
NZ (1) NZ508622A (tr)
PL (1) PL197648B1 (tr)
PT (1) PT1089998E (tr)
RU (1) RU2227142C2 (tr)
SK (2) SK285647B6 (tr)
TR (1) TR200003844T2 (tr)
WO (1) WO1999067252A2 (tr)
ZA (1) ZA200007059B (tr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1186606T4 (da) 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
ATE408612T1 (de) * 1996-11-18 2008-10-15 Biotechnolog Forschung Gmbh Epothilone e und f
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
DE19820599A1 (de) * 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
MXPA01008374A (es) 1999-02-22 2003-06-06 Squibb Bristol Myers Co Epotilonas c-21 modificadas.
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
JP3989175B2 (ja) 1999-04-15 2007-10-10 ブリストル−マイヤーズ スクイブ カンパニー 環状タンパク質チロシンキナーゼ阻害剤
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
AU2508201A (en) * 1999-11-24 2001-06-04 Basf Aktiengesellschaft Fungicidal melithiazole derivatives
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US20020045609A1 (en) * 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
JP2004509899A (ja) * 2000-09-22 2004-04-02 ゲゼルシャフト　フュア　バイオテクノロギッシェ　フォーシュンク　エム　ベー　ハー（ゲー　ベー　エフ） トリアゾロ−エポチロン
EP1414384A4 (en) * 2000-10-13 2005-07-27 Univ Mississippi SYNTHESIS OF EPOTHILONES AND RELATED ANALOGS
BR0206511A (pt) 2001-01-25 2003-10-21 Bristol Myeres Squibb Company Formulação parenteral para análogos de epotilona
CZ20032021A3 (cs) 2001-01-25 2004-05-12 Bristol@Myersásquibbácompany Způsoby podávání analogů epothilonu při léčbě rakoviny
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
CA2438598A1 (en) 2001-02-20 2002-08-29 Francis Y. F. Lee Epothilone derivatives for the treatment of refractory tumors
IL156988A0 (en) 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
CZ20032291A3 (cs) * 2001-02-27 2004-02-18 Gesellschaft Für Biotechnologische Forschung Mbh ( Degradace epothilonů
CA2440555A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
JP2004532888A (ja) * 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
CA2456280A1 (en) * 2001-08-23 2003-03-06 Novartis Ag Cyclopropyl and cyclobutyl epothilone analogs
WO2003026744A1 (en) * 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
WO2003035047A2 (en) * 2001-10-25 2003-05-01 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
US20050227300A1 (en) * 2001-12-07 2005-10-13 Atadja Peter W Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
RU2346686C2 (ru) 2002-01-14 2009-02-20 Новартис Аг Комбинации, включающие эпотилоны и антиметаболиты
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
ES2337134T3 (es) 2002-03-12 2010-04-21 Bristol-Myers Squibb Company Derivados de c3-ciano-epotilona.
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
JP4276171B2 (ja) * 2002-08-02 2009-06-10 ノバルティス アクチエンゲゼルシャフト エポシロン誘導体
KR101173510B1 (ko) * 2002-08-23 2012-08-21 슬로안-케테링인스티튜트퍼캔서리서치 에포틸론, 이의 중간물질과 유사체의 합성 및 이들의 용도
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
TWI291464B (en) 2002-09-23 2007-12-21 Bristol Myers Squibb Co Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
BR0315293A (pt) * 2002-10-15 2005-08-30 Univ Louisiana State Derivados de lactona para o tratamento de hiperparatireoidismo
WO2004045518A2 (en) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
GB0405898D0 (en) * 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
US7893268B2 (en) * 2005-07-27 2011-02-22 University Of Toledo Epithiolone analogues
JP2009516753A (ja) * 2005-11-22 2009-04-23 ザ スクリップス リサーチ インスティテュート 高度に効力を持つエポチロンの化学合成
US7653731B2 (en) * 2006-02-24 2010-01-26 Microsoft Corporation Management of connections to external data
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California POLY THERAPY FOR TREATING CANCER
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics Inc composto de ligação de domìnio bir da iap
WO2008070672A2 (en) 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and cpg rich dna
EP2114429A4 (en) 2007-02-08 2010-05-19 Univ Illinois COMPOSITIONS AND METHODS FOR PREVENTING CANCER WITH CUPREDOXINS
US8435983B2 (en) * 2007-03-23 2013-05-07 The University Of Toledo Conformationally restrained epothilone analogues as anti-leukemic agents
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
KR20110043653A (ko) * 2008-07-03 2011-04-27 파르마 마르 에스.에이. 항종양 마크롤라이드
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
EP3566719A1 (en) 2010-05-18 2019-11-13 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
EP2665493B1 (en) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US9764038B2 (en) 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
EP2924044B1 (en) 2012-11-17 2018-10-31 Beijing Shuobai Pharmaceutical Co., LTD Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
CA2898996A1 (en) * 2013-01-23 2014-07-31 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
EP3010548A1 (en) 2013-06-21 2016-04-27 Innate Pharma Enzymatic conjugation of polypeptides
AU2016340093A1 (en) * 2015-10-16 2018-05-10 William Marsh Rice University Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DK1186606T4 (da) 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
ATE408612T1 (de) 1996-11-18 2008-10-15 Biotechnolog Forschung Gmbh Epothilone e und f
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
NZ337195A (en) 1997-02-25 2001-05-25 Biotechnolog Forschung Gmbh Epothilones with a modified side chain
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DK1005465T3 (da) 1997-08-09 2007-11-05 Bayer Schering Pharma Ag Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse
DE19744135C1 (de) 1997-09-29 1999-03-25 Schering Ag Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe

Also Published As

Publication number Publication date
US6531497B1 (en) 2003-03-11
EP1089998B1 (en) 2006-10-25
IL182744A (en) 2010-05-17
CA2334342C (en) 2012-07-17
US20030203938A1 (en) 2003-10-30
NO20006378L (no) 2001-02-21
CZ20004769A3 (cs) 2001-07-11
BR9911420A (pt) 2001-03-20
AU4774899A (en) 2000-01-10
CY1105863T1 (el) 2011-02-02
CN1306531A (zh) 2001-08-01
CZ301783B6 (cs) 2010-06-23
US7579366B2 (en) 2009-08-25
KR20010083060A (ko) 2001-08-31
JP2002518504A (ja) 2002-06-25
DE69933767D1 (de) 2006-12-07
HK1038358A1 (en) 2002-03-15
SK285647B6 (sk) 2007-05-03
IL139784A (en) 2010-05-17
IL182744A0 (en) 2007-07-24
MXPA00012443A (es) 2004-12-03
CA2334342A1 (en) 1999-12-29
IL139784A0 (en) 2002-02-10
DK1089998T3 (da) 2007-01-15
ES2273502T3 (es) 2007-05-01
KR20090066332A (ko) 2009-06-23
HUP0102711A3 (en) 2002-09-30
KR100864742B1 (ko) 2008-10-22
EP1089998A2 (en) 2001-04-11
AU757854B2 (en) 2003-03-06
NO328417B1 (no) 2010-02-15
NO20006378D0 (no) 2000-12-14
PL197648B1 (pl) 2008-04-30
PL345327A1 (en) 2001-12-17
ID28210A (id) 2001-05-10
EP1741715A1 (en) 2007-01-10
PT1089998E (pt) 2007-01-31
ZA200007059B (en) 2002-01-30
SK19712000A3 (sk) 2001-09-11
KR20080045298A (ko) 2008-05-22
WO1999067252A2 (en) 1999-12-29
HUP0102711A2 (hu) 2001-12-28
US6380394B1 (en) 2002-04-30
NZ508622A (en) 2003-07-25
SK287864B6 (sk) 2012-02-03
WO1999067252A3 (en) 2000-03-16
RU2227142C2 (ru) 2004-04-20
CN1192031C (zh) 2005-03-09
DE69933767T2 (de) 2007-09-13
ATE343573T1 (de) 2006-11-15
JP4681732B2 (ja) 2011-05-11

Similar Documents

Publication Publication Date Title
TR200003844T2 (tr) Epotilon türevleri, sentezleri ve kullanımları
TW357174B (en) Synergistic stabilizer mixture
TR199800602A2 (tr) Dithiolan türevleri, hazirlanmalari ve terapötik etkileri.
NZ507735A (en) Indole derivatives useful for treating malignant and other diseases caused by pathological cell proliferation
TW358808B (en) Morpholine derivatives, preparation thereof and pharmaceutical composition containing the same
NZ231983A (en) Substituted 1,3-diazoles and 1,2,4-triazoles; fungicidal compositions, methods for preparation and combating fungal disease
HK1051680A1 (en) Amino alcohol derivatives
IE893294L (en) Piperidinyl benzimidazoles
DE69609325T2 (de) Derivate des radicicols
TR199902897T2 (tr) Sivi benz-izo-kuinolin türevleri.
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
GB2311780A (en) Piperazine-2,5-dione derivatives as modulators of multidrug resistance
NZ238033A (en) 1-indanone- or 1-tetralone-2'-amidinohydrazone derivatives and pharmaceutical compositions thereof
GB8921792D0 (en) New compositions of matter
MX9603199A (es) Antagonistas de receptores a endotelina.
TW334428B (en) Novel benzodiazepine derivatives
TW372955B (en) Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
TW225989B (tr)
TR199700481A2 (tr) Sefem ve izooksafem türevlerinin hazirlanmasi.
CA2074039A1 (en) Antihypertensive combination
ATE115572T1 (de) N-2-chlorbenzyl-2-oxo- und n-2-chlorbenzyl-2,2,- dioxo-1,2,3-oxathiazolidinderivate, ihre herstellung und ihre verwendung in der synthese von thieno(3,2-c>pyridinderivaten.
ATE105565T1 (de) Pradimicinderivate.
CA2053705A1 (en) Piperazine derivatives
ES2154191A1 (es) Nuevos acetales derivados de los 2-alquil-5-halo-3-(2'-(tetrazol-5-il)-bifenil-4-ilmetil)-3h-imidazol-4-carbaldehidos.
TR200101422T2 (tr) IL-5 inhibe edici 6-azaurasil türevleri